RxDoctor Payments Data

Ameet Singh, MD

Otolaryngology · Washington, DCNPI 1124041439

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.

$1,351in general payments, 2019–2025

Across 32 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$266
  • Medtronic$264
  • Regeneron Healthcare Solutions, Inc.$216
  • Acclarent, Inc$215
  • Integra Lifesciences Corporation$115
  • Optinose US, Inc.$62
  • plus $213 from 8 others
$31,191in research payments, 2019–2025

Across 4 payments — averaging $7797.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$31K

What the payments were for

  • Food & beverage$1,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,351 in reported general payments places this provider in the 65th percentile of 41 otolaryngology providers in District of Columbia.

See all otolaryngology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$151,888
Medicare patients
203
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl90$3,841
Fluticasone Propionate104$2,347
Ipratropium Bromide14$1,064
Mupirocin22$201
Doxycycline Hyclate17$136
Methylprednisolone15$105

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →